TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03164577

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Drum-Assisted Recovery Therapy for Native Americans (DARTNA)
Description: An intervention that utilizes AI/AN drumming as its core component of treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care Plus
Description: Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
Study: NCT01483768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy for morbid obesity
Description: Sleeve gastrectomy or longitudinal gastrectomy for morbid obesity: is a partial gastrectomy without interruption of the gastric continuity. This procedure includes the resection of the great curvature of the stomach, the fundus , except the lesser curvature and the antrum.
Study: NCT02988154

Intervention type: OTHER
Intervention: Simulation training
Description: Simulation training (computer simulation of the procedure, followed by simulation on a dead animal model).

Intervention type: OTHER
Intervention: ''See one, do one'' approach
Description: The participants watch an experienced surgeon perform the EVD placement, after which the participants attempt to perform the procedure independantly on the skull model.
Study: NCT04422743

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline 500 mg plus Homotaurine 50 mg
Description: Citicoline 500 mg plus Homotaurine 50 mg was added to topical therapy
Study: NCT04248803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLUMA (Kulzer GmbH, Germany) desensitizing agent
Description: GLUMA desensitizer is used to reduce tooth sensitivity
Study: NCT03368482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Gym Exercises
Description: Participants in the BrainGym Exercises group performed six of the following BG exercises in every training session they took part in: Cross Crawl, Gravity Glider, Arm Activation, Belly Breathing, Hook-ups, Think of an X, Lazy Eights, Elephant, Space Buttons, The Owl, Energy Yawn, Balance Buttons and The Energizer. All exercises were executed from a sitting position but following the main tenets of the Brain Gym® work routine.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise program for institutionalized older adults.
Description: Participants in the Standard Exercise group took part in a traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
Study: NCT02069951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice a procedural module on a simulator
Study: NCT00746460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CVD risk profile
Description: Cardiovascular risk assessment and behavioral counselling
Study: NCT01279915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0456
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01209988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin 0.4mg
Description: perioperative tamsulosin 0.4mg daily for three weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No medication
Description: No medication
Study: NCT01385423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preparative Regimen
Description: Fludarabine 25 mg/m\^2 x 5 days start day -6, Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (\*if \< 4 months from prior transplant, omit day -4 dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous Recombinant Human IL-15 (rhIL-15)
Description: IL-15 at assigned dose (0.25, 0.5, 0.75 1, 2 and 3 mcg/kg for 3 to 6 patients) intravenously (IV) over 30 minutes once a day beginning day +1 and continuing for 12 doses
Study: NCT01985724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles
Study: NCT01289405

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: mechanical splint to open airway during sleep, considered the gold standard treatment for patients with obstructive sleep apnea

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: mechanical splint to open airway during sleep, considered the gold standard treatment for patients with obstructive sleep apnea
Study: NCT01833975

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Transplantation of Autologous stem cell [MNCs] .
Description: Intra thecal transplantation of Autologous stem cell \[MNCs\],100millions per dose in 3 divided doses at interval of 10 days.
Study: NCT05080920

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rosmalip®
Description: Nutritional Supplement+Usual Care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo+Usual Care
Study: NCT02481882

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: All scanning will be performed using a 7 Tesla Philips Achieva scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands). The volunteers will be scanned with a 32-channel receive coil.

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: All scanning will be performed using a 7 Tesla Philips Achieva scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands). The volunteers will be scanned with a 32-channel receive coil.

Intervention type: DRUG
Group type: OTHER
Intervention: Prohance (Gadoteridol)
Description: A gadolinium based liquid administered intravenously in order to quantify blood flow in the brain using an MR scanner.
Study: NCT00716573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: 0,75 mg bid, 24 months
Study: NCT01985724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: ARM A: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluoruracil
Description: ARM A: 5-fluoruracil 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
Study: NCT00004228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study: NCT02925871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-designed person-centred care transitions
Description: The intervention consists of several elements that aim to meet patients', significant others', and professionals' needs for shared understanding, patient preparedness for homecoming, and coordination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current care transitions
Description: Control group participants will receive current care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
Study: NCT04248803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLUMA (Kulzer GmbH, Germany) desensitizing agent
Description: GLUMA desensitizer is used to reduce tooth sensitivity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLUMA (Kulzer GmbH, Germany) desensitizing agent
Description: GLUMA desensitizer is used to reduce tooth sensitivity
Study: NCT03215030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp alfa
Description: Modakafusp alfa intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp alfa
Description: Modakafusp alfa intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp alfa
Description: Modakafusp alfa intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone.
Study: NCT04246177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) via oral capsules once a day during each 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Placebo
Description: Lenvatinib-matching placebo administered via oral capsules once a day during each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Placebo
Description: Pembrolizumab-matching placebo administered via IV infusion once every 6 weeks (Q6W).
Study: NCT04246177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Conducted as a background procedure of chemotherapeutic and embolic agent(s).
Study: NCT02800902

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral prophylaxis followed by placement of placebo gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Oral prophylaxis followed by placement of rosuvastatin gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Oral prophylaxis followed by placement of atorvastatin gel
Study: NCT02421939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib
Description: tablet, oral
Study: NCT04246177

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Conducted as a background procedure of chemotherapeutic and embolic agent(s).
Study: NCT02421939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LoDAC (Low Dose Cytarabine)
Description: subcutaneous (SC) or intravenous (IV) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: SC or IV injection
Study: NCT00004228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV
Study: NCT01911221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Description: Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain
Study: NCT00525057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: Given SC
Study: NCT03967561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive water-based aerobic training
Description: The intervention will comprise walking/running in shallow pool with progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-progressive aerobic training
Description: The intervention will comprise walking/running in shallow pool without progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
Study: NCT02369523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: Mixture of 50 mL of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine cocktail (PIC)
Description: 400 mg Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.~Sciatic nerve block - 0.125% bupivacaine
Study: NCT03007342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00004228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV
Study: NCT03505645

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular infiltration
Description: The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~Treatment group 1: Periarticular infiltration~Intra-operatively after bone cuts have been made and prior to implant cementation, the multimodal injection will be infiltrated around the knee at 6 specific sites:~1. Medial femoral condyle periosteum~2. Medial gutter~3. Lateral femoral condyle periosteum~4. Lateral gutter~5. Posteromedial capsule~6. Posterolateral capsule

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular infiltration
Description: The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~After implant cementation and watertight joint capsular closure, the multimodal injection will be injected intra-articularly through the closed capsule.
Study: NCT00680693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: 8 weekly 2-hour classes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-educational support group for women with IBS
Description: 8 weekly 2-hour meetings
Study: NCT02421939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEC (Mitoxantrone, Etoposide, Cytarabine)
Description: IV injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)
Description: SC (G-CSF) and IV (Fludarabine, Cytarabine, Idarubicin) injection
Study: NCT01403844

Intervention type: OTHER
Group type: OTHER
Intervention: Carotenoid Depletion
Description: Depletion of carotenoids using a restricted food list
Study: NCT02103218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education, activities, empowerment, racial pride building
Description: Intervention focuses on information aimed toward reducing or preventing risky sex behaviors of minority adolescent females.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health education, activities
Description: Intervention focuses on information regarding general health knowledge and healthy behaviors (not including sex).
Study: NCT06072248

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meropenem
Description: all patients in both groups receive meropenam and put on the ventilators for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: all patients in both groups receive meropenam and put on the ventilators for 2 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bronchoscopy
Description: Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ventilator
Description: ventilator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventilator
Description: ventilator
Study: NCT03676335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA eye gel
Description: The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg
Study: NCT01403844

Intervention type: OTHER
Group type: OTHER
Intervention: Carotenoid Repletion
Description: Carotenoid repletion with provided diet based on dietary guidelines.

Intervention type: OTHER
Group type: OTHER
Intervention: Carotenoid Depletion
Description: Carotenoid depletion using a restricted food list.

Intervention type: OTHER
Group type: OTHER
Intervention: Natural Repletion
Description: Resumption of usual personal diet regimen. No restrictions.
Study: NCT03782948

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard gait training on BART without pelvic perturbations
Description: The Balance Assisted Robot on Treadmill (BART) enables various types of gait training on treadmill with visual feedback. It interfaces to the pelvis of the walking subject in an actuated and admittance-controlled manner, thus providing transparent haptic interaction with negligible power transfer.
Study: NCT03676335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA eye gel
Description: The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA eye gel
Description: The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg
Study: NCT03782948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotised gait training with BART with pelvic perturbations
Description: In addition to the standard gait training, the BART will deliver perturbations in the forward/backward and left/right direction.
Study: NCT03676335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CsA for eye emulsion
Description: The CsA for eye emulsion of 0.4 ml: 0.2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypromellose Eye Drops
Description: Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypromellose Eye Drops
Description: Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypromellose Eye Drops
Description: Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypromellose Eye Drops
Description: Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop
Study: NCT03686761

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A Involvement with the osteotomy site of the surgery
Description: A Involvement with the osteotomy site of the surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A Involvement with the osteotomy site of the surgery
Description: A Involvement with the osteotomy site of the surgery
Study: NCT00089323

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone Marrow Aspiration
Study: NCT02869997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspect BIS XP (A-2000) Bispectral Index Patient Monitor
Study: NCT02288715

Intervention type: OTHER
Intervention: no interventions

Intervention type: OTHER
Intervention: no interventions
Study: NCT02724267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 131I-chTNT-1/B
Description: 29.6 MBq/kg,intravenous administration in 1 hour，1-3 course of treatment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 131I-chTNT-1/B
Description: 29.6 MBq/kg,intravenous administration in 1 hour，1-3 course of treatment
Study: NCT01837732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relational Touch
Description: Relational touch 15 mn  relational touch, hand touch (neck, face and head)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relational:
Description: Relational: 10 mn verbal patient's centered exchanges
Study: NCT04660253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTP Plus Dads
Study: NCT02443519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT for Migraine
Description: 8 75-90 minute individual sessions of the manualized Mindfulness-based Cognitive Therapy plus a manual and homework
Study: NCT05077878

Intervention type: BIOLOGICAL
Intervention: DSPP level in GCF
Description: quantification of DSPP

Intervention type: BIOLOGICAL
Intervention: DSPP level in GCF
Description: quantification of DSPP
Study: NCT02742051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Neoadjuvant endocrine therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Neoadjuvant endocrine therapy
Study: NCT05077878

Intervention type: BIOLOGICAL
Intervention: DSPP level in GCF
Description: quantification of DSPP
Study: NCT02742051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Neoadjuvant chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Neoadjuvant chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Neoadjuvant chemotherapy
Study: NCT01210053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: malate Given orally
Description: Patients receive oral sunitinib malate 25 mg daily in the absence of disease progression or unacceptable toxicity.